Ora Frankel
Psychiatry · Louisville, KYNPI 1700072287
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.2% of the total across 386 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 13.9% — the pattern of someone who eats at a lot of different presentations.
Across 386 payments — averaging $16.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$864
- Lundbeck LLC$676
- Bausch Health US, LLC$646
- Otsuka America Pharmaceutical, Inc.$531
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$328
- Alkermes, Inc.$307
- plus $3K from 24 others
What the payments were for
- Food & beverage$6,05397%
- Education$1723%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 78 | $864 |
| Lundbeck LLC | 34 | $676 |
| Bausch Health US, LLC | 59 | $646 |
| Otsuka America Pharmaceutical, Inc. | 27 | $531 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 14 | $328 |
| Alkermes, Inc. | 13 | $307 |
| Neurocrine Biosciences, Inc. | 16 | $274 |
| Vanda Pharmaceuticals Inc. | 10 | $248 |
| Takeda Pharmaceuticals U.S.A., Inc. | 18 | $237 |
| Corium, LLC | 15 | $233 |
| Ironshore Pharmaceuticals Inc. | 11 | $207 |
| Johnson & Johnson | 12 | $206 |
| Tris Pharma Inc | 11 | $202 |
| Teva Pharmaceuticals USA, Inc. | 13 | $202 |
| Jazz Pharmaceuticals Inc. | 4 | $184 |
| Noven Therapeutics, LLC | 9 | $161 |
| Sunovion Pharmaceuticals Inc. | 10 | $151 |
| Axsome Therapeutics, Inc. | 7 | $145 |
| Adlon Therapeutics L.p. | 5 | $65 |
| Neos Therapeutics, LP | 3 | $56 |
| Supernus Pharmaceuticals, Inc. | 3 | $51 |
| Almatica Pharma LLC | 2 | $44 |
| Shire North American Group Inc | 3 | $41 |
| Alfasigma USA, Inc. | 2 | $36 |
| Idorsia Pharmaceuticals US Inc | 2 | $28 |
| Rhodes Pharmaceuticals L.p. | 1 | $24 |
| MDD US Operations, LLC | 1 | $23 |
| Aytu Biopharma, Inc. | 1 | $18 |
| Collegium Pharmaceutical, Inc. | 1 | $18 |
| Neuronetics, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,225 in reported general payments places this provider in the 85th percentile of 348 psychiatry providers in Kentucky.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 20 | $49,705 |
| VyvanseLisdexamfetamine Dimesylate | 86 | $37,918 |
| TrintellixVortioxetine Hydrobromide | 34 | $33,921 |
| AuvelityDextromethorphan Hbr/Bupropion | 19 | $31,743 |
| Lisdexamfetamine Dimesylate | 58 | $21,084 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 38 | $10,589 |
| QuviviqDaridorexant Hcl | 12 | $7,265 |
| Asenapine Maleate | 14 | $5,532 |
| Aripiprazole | 57 | $5,386 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 33 | $4,876 |
| Lurasidone Hcl | 14 | $4,385 |
| Vilazodone Hcl | 23 | $3,237 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 65 | $3,096 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 26 | $2,239 |
| Alprazolam | 189 | $1,398 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse, Trintellix | $237 | $71,839120 claims |
| AbbVieVraylar | $864 | $49,70520 claims |
| Axsome Therapeutics, Inc.Auvelity | $145 | $31,74319 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $28 | $7,26512 claims |
| Almatica Pharma LLCSertraline Hcl | $44 | $1,06651 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 348 psychiatry providers in Kentucky.
Other psychiatry in Louisville
- Rifaat El-MallakhLouisville$1.6M
- Robert StewartLouisville$651K
- Ali FarooquiLouisville$393K
- Stephanie HallLouisville$106K
- Kelly ClarkLouisville$14K
- Michael HarrisLouisville$13K
- Yelena VaninaLouisville$12K
- Mohamed KhodeirLouisville$9K
- Kevin BaysLouisville$9K
- Terry HaganLouisville$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.